Provided by Tiger Trade Technology Pte. Ltd.

Ligand Pharmaceuticals

284.47
-4.7800-1.65%
Post-market: 283.22-1.2500-0.44%17:17 EDT
Volume:261.16K
Turnover:74.59M
Market Cap:5.67B
PE:29.30
High:294.00
Open:291.48
Low:283.77
Close:289.25
52wk High:326.63
52wk Low:161.82
Shares:19.94M
Float Shares:19.35M
Volume Ratio:1.31
T/O Rate:1.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):9.71
EPS(LYR):6.13
ROE:21.96%
ROA:3.99%
PB:5.86
PE(LYR):46.41

Loading ...

Ligand amends XOMA Royalty merger agreement to add new holding company entity

Reuters
·
May 18

Ligand director John W. Kozarich sells USD 572,598 common shares

Reuters
·
May 15

RBC Capital Keeps Their Buy Rating on Ligand Pharma (LGND)

TIPRANKS
·
May 12

Ligand Pharmaceuticals’ Earnings Call Signals Scaled Royalty Push

TIPRANKS
·
May 12

Ligand Q1 FY26 operating income swings to USD 17.4 million; revenue rises 14% to USD 51.7 million

Reuters
·
May 09

Stock Track | Ligand Pharmaceuticals Soars 5.80% Intraday Following RBC Capital Price Target Hike

Stock Track
·
May 09

Ligand Pharmaceuticals Is Maintained at Outperform by RBC Capital

Dow Jones
·
May 09

RBC Capital Keeps Their Buy Rating on Ligand Pharma (LGND)

TIPRANKS
·
May 08

Ligand Pharmaceuticals Down Over 9%, on Pace for Largest Percent Decrease Since January 2022 -- Data Talk

Dow Jones
·
May 08

Stock Track | Ligand Pharmaceuticals Plunges 7.33% in Pre-Market After Q1 Earnings and Sales Miss Estimates

Stock Track
·
May 07

GUIDANCE: (LGND) Ligand Pharmaceuticals Expects 2026 Adjusted EPS Range $8.50 to $9.50, vs. FactSet Est of $8.99

MT Newswires Live
·
May 07

Ligand Q1 revenue rises 14% on royalty growth

Reuters
·
May 07

Ligand Pharmaceuticals Q1 Adj. EPS $1.63 Misses $1.82 Estimate, Sales $51.722M Miss $58.696M Estimate

Benzinga Earnings
·
May 07

BRIEF-Ligand Pharmaceuticals Q1 EPS USD -0.67

Reuters
·
May 07

Ligand Pharmaceuticals Outlook FY Revenue USD 270-310 Million

THOMSON REUTERS
·
May 07

Orchestra BioMed receives $15M payment from Ligand

TIPRANKS
·
May 07

Ligand CLO Andrew Reardon disposes of common shares worth $1,155,172.85

Reuters
·
May 05

Ligand, Viking dispute TR-Beta program termination under license agreement

Reuters
·
May 01

Bank of America Securities Keeps Their Buy Rating on Ligand Pharma (LGND)

TIPRANKS
·
Apr 30

Ligand Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Apr 30